- Home
- ACRS vs CDNL Comparison
ACRS vs CDNL Comparison
Compare ACRS & CDNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACRS | CDNL |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.5M | 888.6M |
| IPO Year | 2015 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ACRS | CDNL |
|---|---|---|
| Price | $4.51 | $29.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | $10.18 | ★ $54.25 |
| AVG Volume (30 Days) | ★ 2.4M | 500.7K |
| Earning Date | 11-05-2026 | 08-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ 0.53 |
| Revenue | $1,683,000.00 | ★ $456,045,369.00 |
| Revenue This Year | N/A | $95.00 |
| Revenue Next Year | N/A | $20.19 |
| P/E Ratio | ★ N/A | $52.66 |
| Revenue Growth | N/A | ★ 44.69 |
| 52 Week Low | $1.74 | $21.98 |
| 52 Week High | $6.60 | $96.40 |
Technical Indicators
Market Signals| Indicator | ACRS | CDNL |
|---|---|---|
| Relative Strength Index (RSI) | 40.21 | 40.14 |
| Support Level | $4.99 | $23.33 |
| Resistance Level | $5.15 | $35.76 |
| Average True Range (ATR) | 0.32 | 1.95 |
| MACD | -0.03 | 0.67 |
| Stochastic Oscillator | 19.62 | 47.85 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
About CDNL Cardinal Infrastructure Group Inc. Class A Common Stock
Cardinal Infrastructure Group Inc provides a comprehensive suite of infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. The company provides wet utility installations (water, sewer, and stormwater systems), as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services. It derives all revenue in the United States of America from construction projects based in North Carolina and South Carolina.